JNJ

Johnson & Johnson

JNJ · CIK 200406

Latest 10-K filed February 11, 2026 · period ending December 31, 2023

Headline figures

Revenue

—

Top-line sales for the most-recent fiscal year

Net income

$35.15B

+95.9% vs prior year

Profit after all expenses, taxes, interest

FY2025 · 10-K

EPS (diluted)

$13.72

+103.9% vs prior year

Net income per diluted share outstanding

FY2025 · 10-K

Op. cashflow

$22.79B

+7.5% vs prior year

Cash actually generated by the business

FY2025 · 10-K

Balance sheet

Total assets

$180.10B

Everything the company owns

FY2025 · 10-K

Total liabilities

$108.61B

Everything the company owes

FY2025 · 10-K

Stockholders equity

—

Assets minus liabilities (book value)

Long-term debt

$30.65B

Debt due more than 12 months out

FY2025 · 10-K

Read the source

All figures on this page were filed by Johnson & Johnson with the SEC and pulled directly from EDGAR's XBRL CompanyFacts API. Click below to view the latest annual report (10-K) in full.

Open latest 10-K on SEC EDGAR →

Not investment advice. Figures sourced from the SEC's XBRL CompanyFacts API — public-domain federal records. Companies occasionally restate prior-year numbers; we show the latest filed value per fiscal year.